| Catalog No. | HY057066 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Humanized |
|---|
| Isotype | scFv-TCR |
|---|
| Expression system | Mammalian Cells |
|---|
| Species | Human |
|---|
| Clonality | Monoclonal |
|---|
| Target | CD3E, gp100 peptide-HLA Complex, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, T-cell surface glycoprotein CD3 epsilon chain |
|---|
| Endotoxin level | Please contact with the lab for this information. |
|---|
| Purity | >95% as determined by SDS-PAGE. |
|---|
| Purification | Purified by Nickel column. |
|---|
| Accession | P07766 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 9mM Citric acid monohydrate, 41mM Na2HPO4, 1% Mannitol, 5% Trehalose, 0.02% Tween 20, 2mM DTT, pH 6.5. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
|---|
| Alternate Names | Bispecific fusion protein, CAS: 1874157-95-5 |
|---|
| Background | Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells. |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
